IDH1 and central nervous system cancer: Here, we outline key metabolic alterations, epigenetic changes and redox imbalance, which might not be uniform across IDH mutant gliomas and ongoing targeted therapeutic options, with several clinical trials specific to IDH inhibition recently published.